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Abstract
Background: Multiple breast cancer gene expression profiles have been developed that appear to provide similar
abilities to predict outcome and may outperform clinical-pathologic criteria; however, the extent to which
seemingly disparate profiles provide additive prognostic information is not known, nor do we know whether
prognostic profiles perform equally across clinically defined breast cancer subtypes. We evaluated whether
combining the prognostic powers of standard breast cancer clinical variables with a large set of gene expression
signatures could improve on our ability to predict patient outcomes.
Methods: Using clinical-pathological variables and a collection of 323 gene expression “modules”, including 115
previously published signatures, we build multivariate Cox proportional hazards models using a dataset of 550
node-negative systemically untreated breast cancer patients. Models predictive of pathological complete response
(pCR) to neoadjuvant chemotherapy were also built using this approach.
Results: We identified statistically significant prognostic models for relapse-free survival (RFS) at 7 years for the
entire population, and for the subgroups of patients with ER-positive, or Luminal tumors. Furthermore, we found
that combined models that included both clinical and genomic parameters improved prognostication compared
with models with either clinical or genomic variables alone. Finally, we were able to build statistically significant
combined models for pathological complete response (pCR) predictions for the entire population.
Conclusions: Integration of gene expression signatures and clinical-pathological factors is an improved method
over either variable type alone. Highly prognostic models could be created when using all patients, and for the
subset of patients with lymph node-negative and ER-positive breast cancers. Other variables beyond gene
expression and clinical-pathological variables, like gene mutation status or DNA copy number changes, will be
needed to build robust prognostic models for ER-negative breast cancer patients. This combined clinical and
genomics model approach can also be used to build predictors of therapy responsiveness, and could ultimately be
applied to other tumor types.
Background
Genomic profiles have significantly improved our ability
to prognosticate in breast cancer patients [1,2]. Several
of these genomic predictors such as the NKI 70-gene
signature (Mammaprint, Agendia) [3,4] or the Oncoty-
peDX Recurrence Score (RS, Genomic Health) [5] are
commercially available and commonly used. We and
others have shown that these and other prognostic gene
expression profiles are, in fact, similar in terms of out-
come predictions despite a lack of gene overlap, suggest-
ing that they each track a common set of biologic
characteristics [6,7]. Since then, numerous signatures
with the potential for increasing prognostic accuracy
have been reported. Some of these have been developed
to track activated molecular signalling pathways [8-19]
and/or particular biological processes such as cell prolif-
eration [17,18,20-22], hypoxia [23-26], cell differentia-
tion [27-30], immune cell processes [27,31,32] and
wound responses [33-36]; other signatures have been
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apy [37,38] or biologic therapies [39,40].
Many studies have examined the prognostic signi-
ficance of genomic biomarkers along with clinical-
pathological variables and often shown that both provide
independent information [41-44]; however, very few stu-
dies have attempted to create integrated prognostic
models that contain both genomic and clinical biomar-
kers [45]. We have recently shown that integration of
one pathological variable (i.e. tumor size) with one
genomic signature (i.e. intrinsic subtypes) outperforms
either strategy alone in terms of outcome prediction
[46], suggesting that both data types can provide inde-
pendent prognostic power and be combined into a sin-
gle model. With the explosion of signatures developed
with distinct biologic processes in mind, it makes sense
to take this approach one step further and develop mod-
els that include not only clinical and genomic informa-
tion, but systematically examines inclusion of multiple
genomic signatures in an effort to further hone prognos-
tication beyond one profile versus another.
In this study, we developed a prognostic model in sys-
tematically untreated node-negative breast cancer
patients derived from multiple commonly used clinical
variables and a large database of gene expression mod-
ules, and we confirmed that models that incorporate
both clinical and genomic variables are the most accu-
rate for outcome predictions for newly diagnosed
patients with node-negative breast cancer. Importantly,
this approach to model development can also be used to
predict responsiveness to therapy and could be general-
ized to other tumor types.
Methods
Patient Populations
A single large dataset of homogenously treated patients
was created by combining 5 different publicly available
clinically-annotated microarray datasets of node-negative
breast cancer patients treated with local therapy only,
and no adjuvant systemic therapy: van de Vijver et al. [4],
Wang et al.[47], Loi et al.[48], Ivshina et al.[49], and the
University of North Carolina (UNC) [13,14,50], where 4
new patients were included (GEO accession number of
the UNC data, GSE15393). The gene expression data was
combined using the batch effect adjustment by the Dis-
tance Weighted Discrimination (DWD) method [51].
Of the 666 patients included in this combined dataset,
550 (83%) had complete data on relapse-free survival
(RFS, defined as the time to first relapse [local or dis-
tant]) and clinical variables (tumor size, histological
grade, and estrogen receptor [ER]), and were included
for further analyses using a 7-year cut-point for RFS.
For the HER2 “clinical status”, which was not available
for most studies, we used a gene expression surrogate
based on the mRNA levels of the HER2 gene, using the
top 20% rank order highest expressers as the cutoff
value for calling a tumor “HER2-positive"; the chosen
cutoff value for HER2 positivity was based on a popula-
tion-based study of breast cancer[52].
We examined the ability of this approach to predict
pathological complete response (pCR) rate to neoadju-
vant chemotherapy in a dataset from Popovici et al.
(MDACC)[37,53], which includes 225 pre-treated sam-
ples/patients (MDACC225) that received neoadjuvant
anthracycline/taxane-based chemotherapy and had com-
plete clinical data. pCR was defined as the absence of
invasive cancer in the breast and axillary lymph nodes.
Gene expression Modules
We defined modules as sets of co-expressed genes that
were considered as a functional unit. Using multiple
approaches, we built a collection of 323 gene expression
modules, including 115 gene lists obtained from 53 pub-
lications: (1) 221 modules were built using the median
expression of all genes within the module that homoge-
neously expresses these genes (i.e. all genes in the mod-
ule were high or low together within a given sample).
The sources of the selected homogenous gene lists were
the following: 50 were identified by bicluster analyses
[54] using the microarray dataset of 359 human breast
tumors and 8 normal breast samples (i.e. the aforemen-
tioned 2/3 training set); 52 modules were identified
from an unsupervised hierarchical clustering analysis of
the same human breast tumor database; 50 were identi-
fied by bicluster analyses using microarray data of 122
mouse mammary tumors[13]; 56 were identified from
unsupervised hierarchical clustering analysis of the same
mouse mammary database; 13 were identified from pre-
viously published gene lists [13,14,17,18,21,26,35,55].
(2) 77 modules were represented as the first Principal
Component of previously published gene lists [3,8-10,12,
13,15,19,20,22,23,25,27-32,34,36,37,40,56-66] that
showed heterogeneous expression patterns (i.e. the gene
list contained genes with high and low expression within
ag i v e ns a m p l e ) .( 3) 22 modules were correlations to
previously published training dataset centroids
[4,9,11,16,24,33,38,39,50,67,68]. (4) 3 modules were built
from previously published gene expression prognostic
models [5,46,47]. We acknowledge that our implementa-
tion of some of the previously published signatures may
be suboptimal, however, we attempted within reason, to
apply each signature as published. All modules, with
gene lists and references, can be found in Additional
File 1.
Statistical Analysis
The various modules and clinical variables (tumor size,
histological grade, ER and HER2 status) were evaluated
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(LASSO) method to build prognostic models using
a Cox proportional hazards approach[69]. For all
analyses, a training set (~2/3) stratified by data source,
platform and clinical variables was used to derive the
modules and build a model, which was then applied to
the testing set (~1/3) (10-fold cross-validation). We
defined “success” of a model when prognostic signifi-
cance for RFS (p < 0.05 by the Cox Model) was shown
on both the training and testing sets. Survival curves
were analyzed and compared with the use of the
Kaplan-Meier method and the log-rank testing, and
hazard ratios were derived from the Cox proportional
hazards model. For the Kaplan-Meier analyses, patients
were stratified into high and low-risk groups based on
their respective risk score, which was defined as the nat-
ural logarithm of the hazard ratio with a chosen cut-off
value for stratification into high and low-risk groups of
zero. To further examine the most frequently selected
modules and/or clinical variables that build successful
prognostic combined models, we repeated 200 times the
previous combined model-building procedure (i.e. by
randomly splitting the training and testing sets), and
then we calculated the frequency of selection of each
module/clinical variable among these 200 successful
models. Statistically over-represented (p < 0.001) biolo-
gical processes within modules were identified with
EASE http://david.abcc.ncifcrf.gov/.
The prognostic ability of the reproducible models and
known prognostic predictors was further characterized
by calculating the concordance index (C-index) [70].
The C-index is a measure of the probability that, given
two randomly selected patients, the patient with the
worse outcome is, in fact, predicted to have a worse
outcome. This measure is similar to an area under the
receiver operating characteristic curve, ranging from 0.5
to 1. For each cohort, we used the model built from the
training set to calculate the C-index of the testing set.
We repeated this procedure 200 times by randomly
splitting the training and testing sets, and then we cal-
culated the mean of the C-indexes of the 200 testing
sets evaluated. Because they so strongly influenced prog-
nostic models, and in order to illuminate other relevant
signatures and biologic processes, we repeated the same
analyses after excluding the NKI 70-gene signature [3,4],
the OncotypeDX RS [5], the Rotterdam 76-gene signa-
ture [47] and the recently described Risk of
R e l a p s e( R O R )s c o r eb a s e do nt h ei n t r i n s i cs u b t y p e s
(ROR-S) [46].
To predict pCR, we randomly split the MDACC225
[37,53] database into a training set (n = 150, ~2/3) and
a testing set (n = 75, ~1/3), stratified by pCR and the
clinical parameters HER2 and ER. HER2-positive
patients who received trastuzumab (n = 4) and patients
without complete clinical data (n = 1) were excluded
(thus giving 225 patients). Using clinical variables (ER,
histological grade, tumor size and HER2) and 318 mod-
ules (after excluding the Response_Predictor_MDACC
[37,53], ROR-S [46], NKI 70-gene signature [3,4], the
OncotypeDX RS [5], and the Rotterdam 76-gene signa-
ture [47]), we built pCR predictive models using clinical
variables only, genomic variables only and a combina-
tion of both in the training set, and applied them in the
testing set (n = 75) using a LASSO plus Logistic Regres-
sion approach. We then analyzed the receiver operating
characteristic (ROC) curve for both the training and
testing sets, and calculated the area under the ROC
curve (AUC). In Additional File 2 we also calculated the
AUC using the Response_Predictor_MDACC [37] mod-
ule, which was trained and test in a subset of patients of
the MDACC225 database [37]. All statistical analyses
were performed with the use of the R software, version
2.9.0 http://www.r-project.org.
Results
Model Building and Risk Predictions
In order to examine the potential of new prognostic
models, a large and homogenously treated data set of
breast cancer patients was created by combining
together systematically untreated (i.e. no systemic adju-
vant therapy) patients; the clinical and pathologic char-
acteristics of the 550 patient dataset of node-negative,
local therapy-only, breast cancer patients from the
public domain are described in Table 1. The majority
of patients had ER-positive (71.8%) and HER2-negative
(80%) tumors, tumor size <2 cm (56.2%), and histologi-
cal grade 1-2 (50.9%). The median follow-up of this
population was 7.0 years (average 5.3 years). Tumor
size, ER status, HER2 status, and grade were each
prognostic for 7-year RFS (Figure 1), confirming that
the combined dataset shows the expected outcomes for
known biomarkers, and suggesting that the
gene expression-based HER2 status designation (see
Methods) was performing appropriately. No statistical
significant differences for outcome were observed
across the datasets that were combined together here
(Additional File 2).
Along with clinical-pathological variables we applied
323 different modules to the combined dataset (Figure 2).
Using a Cox proportional hazards approach with
LASSO Regression [69], which is a method of model
building that can handle large numbers of potentially
co-linear variables, all patients and different patient sub-
sets defined by clinical parameters or intrinsic molecu-
lar subtyping were tested for prognostic model building.
Successful prognostic models were built for (a) all
patients (Figure 3a) and (b) patients with ER-positive
tumors (Figure 3b). Similar significant outcome
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defined as having Luminal tumors (i.e. Luminal A and B
combined) and for ER-positive/HER2-negative patients
(Additional File 2). Despite the fact that several modules
were prognostic in univariate Cox proportional hazard
analyses for either ER-negative or HER2-positive disease,
no multivariate models could be built that held up in
the both the training and testing sets for these patient
subsets (Figure 3c-d). Interestingly, the combined model
testing set for ER-negative disease approaches signifi-
cance; however, there is little evidence of prognostic
ability in HER2-positive disease. As expected, no prog-
nostic models were obtained when we stratified patients
based on the intrinsic subtype (Basal-like or HER2-
enriched tumors), or based upon ER and HER2 status
(ER-negative/HER2-negative, ER-negative/HER2-positive
and ER-positive/HER2-positive tumors); it should be
noted, however, that the sample size for some of the
clinically defined patient subsets was small, which may
have hindered successful model building.
Table 1 Characteristics of the Combined Dataset
Training (~2/3) Testing (~1/3)
Characteristics Total N % N N P-value*
Subjects 550 359 191 -
ER + 395 71.8% 259 136 0.89
- 155 28.2% 100 55
Size < 2 cm 309 56.2% 198 111 0.56
≥ 2 cm 241 43.8% 161 80
HER2* + 110 20.0% 73 37 0.88
- 440 80.0% 286 154
Grade 1 98 17.8% 63 35 0.45
2 182 33.1% 113 69
3 270 49.1% 183 87
Published Dataset^ Ivshina 137 24.9% 89 48 1
Loi 42 7.6% 28 14
NKI 141 25.6% 92 49
UNC 33 6.0% 22 11
Wang 197 35.8% 128 69
Platform Affymetrix 376 68.4% 245 131 0.99
Agilent 174 31.6% 114 60
Subtype (PAM50) Luminal A 156 28.4% 98 58 0.92
Luminal B 131 23.8% 85 46
HER2-enriched 83 15.1% 56 27
Basal-like 106 19.3% 72 34
Normal Breast-like 74 13.5% 48 26
*HER2 status is based on ERBB2 mRNA levels. P-values have been calculated based on a Chi-square test.
^compiled from Ivshina et al., 2006; Loi et al., 2007; van de Vijver et al., 2002; Wang et al., 2005; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15393.
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Figure 1 Kaplan-Meier survival estimates of relapse-free
survival (RFS) among 550 patients, according to tumor size,
clinical estrogen receptor (ER) status, HER2 mRNA status, and
histological grade. P-values were obtained from the log-rank test,
and (+) denotes observations that were censored owing to loss to
follow-up or on the date of last contact.
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Page 4 of 15Modules Source Methods #Modules
Published Gene lists Median 13
Bi-Cluster identified from Mouse Median 50
Bi-Cluster identified from Human Median 50
Unsupervised Cluster from Human Median 52
Unsupervised Cluster from Mouse Median 56
Published Gene lists First PCA 77
Published Gene lists Correlations 22
Published Models Hazard Ratio 3
Total Modules 323
NKI (141) + UNC (33) + Loi (42) + Ivshina (137) + Wang (197)
Total 550 Samples
Train (359 Samples)                     Test (191 Samples) +
Randomly split into training (2/3) and testing sets (1/3)
550 patients
M
o
d
u
l
e
s
A
B
Figure 2 Depiction of the combined breast tumor dataset.( A) Table summarizing the different approaches used to obtain the various
modules. PCA, principal component analysis. (B) Hierarchical cluster analysis of 323 gene expression modules (rows) across the microarray data
of 550 node-negative breast cancer patients (columns). All samples were stratified by source, platform and clinical variables, and randomly split
into a training (~2/3) and testing (~1/3) sets.
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Patients
In order to robustly identify prognostic variables, 200
rounds of training and testing were performed for each
patient subset discussed above. Examination of the most
frequently selected modules and clinical variables for the
“all patients’ group was revealing of the underlying biol-
ogy (Figure 4a). Starting with all patients, the expression
of several modules, in addition to tumor size and grade,
was clearly associated with either a poor or good prog-
nosis in the combined model. Included within the most
frequently selected poor outcome modules were the
Rotterdam 76-gene signature [47], the OncotypeDX RS
(GHI_RS) [5], and the correlation to the HER2-enriched
intrinsic subtype centroid (Scorr_Her2) [50]. In addition,
other previously unpublished signatures derived from
unsupervised hierarchical clustering analyses of human
breast tumors and mouse mammary tumor datasets
were also frequently selected to build prognostic models
for all patients. Three of these poor prognostic modules
were highly enriched with genes involved in cell cycle/
proliferation (MM_Red10), vascular smooth muscle con-
traction (MUnknown_34), and mRNA processing/spli-
cing (Unknown_9 and MUnknown_1); it is likely that
our “undescribed” cell cycle/proliferation module is
merely reflecting many previously described proliferation
signatures [71], which is a known and powerful predic-
tor of outcomes for node-negative breast cancer
patients.
Increased expression of other unpublished modules
was associated with good outcome. Several of these were
highly enriched with genes involved in immune response
(IGG_Cluster; and HS_Red16), extracellular space
(HS_Green19 and Fibrinogen_Cluster), transcription
D. HER2-positive Patients (N = 110)
A. All Patients (N = 550) B. ER-positive Patients (N = 395)
C. ER-negative Patients (N = 155)
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Figure 3 Survival prediction analyses of the different Cox models.( A) Models for all patients; (B) Models for ER-positive patients; (C) Model
for ER-negative patients; (D) Models for HER2-positive patients. 1) Hazard ratio and p-value of the Cox proportional hazard model (Cox-model),
for both the training and testing sets, respectively; 2) Kaplan-Meier survival estimates of relapse-free survival (RFS) among training and testing
sets, respectively, according to each model. Patients were stratified into high-risk (red curve) and low-risk (blue curves) groups based on their
respective risk score, which was defined as the natural logarithm of the hazard ratio. The chosen cut-off value for stratification into high and
low-risk groups was zero. P-values were obtained from the log-rank test. + denotes observations that were censored owing to loss to follow-up
or last contact.
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MUnknown_34 24% Bone_Metastasis_Underexpressed 24% 58
Oncogenic_BCAT 27% 10 VEGF_13genes 24% 26
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VEGF_13genes 47% 26 MNOtch4 43%
MM_Red10 50% HER2_Amplicon 44%
ADM_S100A10_A110NDGR1_Cluster 56% ADM_S100A10_A110NDGR1_Cluster 47%
HER2_Amplicon 71% MM_Red10 47%
Scorr_Her2 74% 50 16q24x 55%
Tumor Size 75% Tumor Size 61%
16q24x 89% MUnknown_30 72%
Histological Grade 100% Histological Grade 94%
Rotterdam_76_Gene 100% 47 Rotterdam_76_Gene 99% 47
Figure 4 Most frequently selected modules and clinical variables that build successful combined models for all patients (A) and ER-
positive patients (B). Modules in blue identify those modules and/or clinical variables that were evaluated in the combined model in Fig. 2.
Colored squares identify the modules and/or clinical variables association with either poor (red) or good (green) prognosis. Freq, frequency of
selection of a particular module/clinical variable among 200 successful models; Ref, references of previously published modules.
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Page 7 of 15(MHistone) and cation transport (MM_Red21). Of note,
the IGG_Cluster (Immunoglobulin) 14-gene module,
which was identified by unsupervised clustering of
human breast tumors, was selected in 196 of 200
combined models (98%). Consistent with our findings,
data from a recent report suggests that, besides prolifera-
tion, the combination of immunity and RNA splicing
processes may have a high prognostic impact in breast
cancer [43].
Among the rest of the modules that frequently com-
prised the combined model for all patients, it is interest-
ing to note that two of them were derived from a single
study that evaluated the transcription factor E2F1-
dependent gene expression program [22], two others
were derived from predictions of b-catenin and MYC
pathway deregulation in cancer cell lines [10], and
another one was likely tracking stem cell-like biological
processes [12].
Selected Modules for Outcome Prediction for ER-positive
Tumors
T h em a j o r i t yo fc o m b i n e dm o d e l sb u i l tf o rE R - p o s i t i v e
patients included grade, tumor size, and various mod-
ules whose expression was associated with either poor
or good prognosis (Figure 4b). Among the 40 most fre-
quently selected modules, 31 (77.5%) were previously
selected to build combined models for all patients, sug-
gesting that outcome predictions for all patients is being
largely driven by the ER-positive patient subset. Impor-
tantly, the Rotterdam 76-gene signature [47], the NKI
70-gene signature [3,4] and the OncotypeDX RS [5],
which were specifically designed to risk stratify early-
stage ER-positive breast cancer, were found among the
top most frequently selected modules that build the
final combined model. In addition, high expression of
the previously described IGG_Cluster 14-gene immune
response module was also found highly associated with
good prognosis in this clinically identifiable breast can-
cer subtype.
We also repeated the analysis without the four best-
known prognostic profiles (i.e. the Rotterdam 76-gene
index [47], OncotypeDX RS [5], NKI-70-gene signature
[3,4] and ROR-S [46]); in this secondary analysis, 31 of
the 40 most frequently selected modules that built the
previous combined models for ER-positive patients were
again selected, including tumor size and grade (Addi-
tional File 2). However, two previously unobserved and
highly selected modules were identified that were the
HS_Red23 module that was present in 143 of 200 mod-
els (71.5%, which mainly tracks cell cycle/proliferation),
and the correlation to the Luminal A intrinsic breast
cancer subtype centroid (Scorr_LumA), which was pre-
sent in 177 of 200 models (88.5%) and, as expected, was
associated with good outcome. Again, no prognostic
models could be built for ER-negative, or HER2-positive
patients, that were successful on both the training and
test sets.
Performance of the Clinical, Genomic and Combined
Models
The prognostic ability of clinical variables, genomic vari-
ables and a combination of both was further character-
ized by calculating the concordance index (C-index) [70]
in the testing sets of (a) all patients and (b) ER-positive
patients after 200 randomizations into training and test-
ing sets (Figure 5A); we acknowledge that these rounds
of training and testing show dependency in that samples
from one round of training will become test samples in
other rounds, but given the limitations of this data set
in terms of size and diversity, we felt this to be a good
means of assessing the relative accuracy of a diverse set
of genomic and pathological predictors. In both cohorts
(all patients and ER+ only), there was an improvement
in prediction with the use of genomics relative to the
model of clinical variables only (Genomics.323 vs. Clini-
cal). More importantly, a combination of clinical and
genomic variables (Combined.323) showed an improve-
ment over either predictor alone in both patient cohorts
(Combined.323 vs. Genomics.323) even when the prog-
nostic signatures NKI 70-gene signature [3,4], the Onco-
typeDX RS [5], the Rotterdam 76-gene signature [47]
and the recently described Risk of Relapse score (ROR)
based on the intrinsic subtypes (ROR-S) [46] were
removed from the analysis (i.e. Combined.319). Indeed,
the C-Index of the Combined.319 model was superior
to the Genomics.319 model in 77% of the 200 rounds of
testing when using all patients (Figure 5B), as were most
other instances of a combined model versus the geno-
mic only version.
The performance of the clinical, genomic and com-
bined models in all patients and ER-positive patients
was also compared to the other known 4 prognostic sig-
natures with and without the addition of clinical vari-
ables (Figure 5A). It should be noted that a subset of
patients in this combined dataset were part of the train-
ing dataset used to derive all these prognostic signa-
tures, except for the OncoTypeDX RS [5]. Nonetheless,
as shown in Figure 5A, the Combined.323 models mod-
estly improved the concordance index in all patients (i.e.
0.6844 vs. 0.6622 ROR-C) or performed similarly in ER-
positive patients (i.e. 0.6798 vs. 0.6764 ROR-C) as did
the other known prognostic predictors when combined
with clinical variables. This data suggests that combining
clinical variables with a single genomic module is better
than either one alone, and that combining clinical vari-
ables with a single module such as the OncoTypeDX RS
(21 genes) can perform similarly as a combined model
that includes hundreds of signatures.
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B.  Frequency of C-Index superiority for each model (rows) when compared to the other
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A
Figure 5 C-Index evaluations of the various models analyzed.( A) Performance of clinical, genomic and combined models in the testing sets
of all patients and ER-positive patients. Each patient subset was randomly split into a training set (~2/3 of cases) and a testing set (~1/3 of
cases). We then used the model built from the training set to calculate the C-index of the testing set. We repeated this procedure 200 times
and then calculated the mean of the C-index for each model. The performance of established prognostic predictors (OncoTypeDX RS, NKI 70-
gene signature, 76-gene Rotterdam index, the risk of relapse based on intrinsic subtyping [ROR_S]) with or without the addition of clinical
variables was also estimated. (B) Frequency of superiority of the C-Index for each model (rows) when compared to the other models (columns)
in 200 testing sets of all patients. Each row represents a model, which is then compared to all other models/columns, where a higher number
indicates that the row model was superior to the model in the column that fraction of the 200 times tested.
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Page 9 of 15Prediction of Response to Neoadjuvant Chemotherapy
To show the potential application of this combined
approach in predicting treatment response, we applied
the different genomic modules, along with clinical vari-
ables (tumor size, HER2, ER, and histological grade), to
225 patients with breast cancer treated with a taxane
and anthracycline containing neoadjuvant chemotherapy
regimen [37,53] (i.e. T/FAC). We were able to build sta-
tistically significant combined models for pCR predic-
tion using 150 patients (training data), and obtained
an average accuracy of 81% in the testing set (n = 75)
(Figure 6a). Among the modules and clinical variables
selected to build the combined model, HER2 status, a
module that tracks immune system response, cell prolif-
eration (HS_Red1), and a module that tracks cell-
adhesion/differentiation (HS_Red8) were associated with
pCR (Figure 6b), while ER status and correlation to the
Luminal A intrinsic breast cancer subtype centroid
(Scorr_LumA) were associated with non-pCR. Interest-
ingly, two previously published modules of non-taxane
chemotherapy responsiveness (Scorr_S329_R and
Scorr_329_L)[38] were selected in the combined model.
Once again, the combined model outperformed the clin-
ical or genomics models only as assessed by AUC
values.
Discussion
Both genomic biomarkers and clinical parameters pro-
vide prognostic powers [2,7,41-43], however, very few
studies have attempted to combine these disparate data
types into a single statistical model [45,46]. To address
this challenge we undertook a comprehensive evaluation
of the prognostic ability of hundreds of genomic mod-
ules in combination with clinical variables, and evalua-
tions of well known genomic predictors alone and in
combination with clinical variables. An important caveat
to these analyses is that for all published predictors
tested here, each lost genes due to the data set combin-
ing, and a common data normalization method was
used, and thus we caution against interpreting these
data to mean that one specific predictor is better than
another. Instead, these exploratory and comparative ana-
lyses have highlighted important concepts that should
be the foundation for future studies. Specifically, we
show that hundreds of genomic signatures are only
slightly better than a few well developed signatures, and
that the integration of gene expression signatures and
clinical-pathological factors can improve prognostication
in patients with lymph node-negative ER-positive breast
cancers. However, for ER-negative and HER2-positive
breast cancer patients, other variables beyond gene
expression and clinical-pathological variables will be
needed to build robust prognostic models. Alternatively,
ER-negative or HER2-positive patients may have a
stereotypical poor prognosis, and thus, building predic-
tive models of therapy responsiveness would be much
more relevant for these two disease subtypes.
While proliferation-related genes are an important
part of many prognostic gene sets, these signatures
show no prognostic value when the analysis is limited to
ER-negative patients, as has been shown before [72].
T h em a j o r i t yo fe s t a b l i s h e dp r o g n o s t i cs i g n a t u r e sw e r e
mainly designed for ER-positive breast cancer patients.
The NKI 70-gene signature [3,4] included a subgroup of
patients with ER-negative and HER2-positive disease in
their validation studies, however, this and other signa-
tures developed using all patients are heavily influenced
by proliferation and ER-related genes, and therefore,
classify almost all of these highly proliferative ER-
negative tumors into the high risk category [6]. Despite
including signatures that track many other distinct bio-
logical processes, no modules or combination of mod-
ules were able to build robust models for ER-negative,
or HER2-positive patients. However, it is interesting to
note that in the ER-negative population tested here, the
expression of the IGG_Cluster immune response mod-
ule was associated with a favorable outcome in univari-
ate analyses, and this module was included, along with
gene lists that track apoptosis and developmental pro-
cesses, in the combined model for the ER-negative train-
ing set (data not shown); however, these predictors were
not statistically significant in the test set. These negative
results should be interpreted with caution as failed pre-
dictions may be due to the technical limitations of this
dataset, however, these results do suggest that studies
focusing on the specific biological role of immune cells
on tumor progression and/or response to treatment may
be warranted in ER-negative tumors. Concordant with
our findings, previous studies [31,32,73,74] have
suggested that the absence of immune response related-
genes might be associated with the development of
distant metastases and therefore poor outcome in
HER2-positive and ER-negative breast cancer.
Although the gene lists of the majority of “selected”
modules/signatures were largely non-overlapping, signif-
icant agreement in outcome predictions for individual
patients was observed, which confirms and extends our
previous observations [6] that different modules can
reflect similar biological processes despite small overlaps
in gene identity. For example, many signatures that are
likely tracking proliferation were commonly selected
including the OncotypeDX RS [5], a signature of chro-
mosomal instability (CIN70) [21], and two signatures
that recapitulates the loss of the retinoblastoma gene
[17,18], all of which showed a cluster correlation of ~0.8
(Additional File 2). Conversely, other highly correlated
signatures showed a high negative correlation to these
proliferation-related modules, which is the case for the
Fan et al. BMC Medical Genomics 2011, 4:3
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Figure 6 Integration of clinical and genomic variables to predict pathological complete response (pCR) after anthracycline/taxane-
based chemotherapy using Popovici et al. dataset (n = 225).( A) Area under the receiver operating characteristic curve (AUC) for clinical,
genomic and combined models in the training and testing sets. (B) Modules and clinical variables that built the combined model evaluated in
section (A). Colored squares identify the modules and/or clinical variables association with pCR (red) or non-pCR (green), respectively. Ref,
references of previously published modules. Note: Response_Predictor_MDACC, OncoTypeDX RS, NKI 70-gene signature, 76-gene Rotterdam
index and ROR-S have been removed for this analysis.
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Page 11 of 15estrogen and GATA3-regulated signatures [9,40],
immune response signatures [27,31], the NKI good
prognostic signature [3,4], signatures that track cell dif-
ferentiation [30], and lack of response to chemotherapy
[37].
While we have recapitulated known biology and made
novel observations that are relevant to breast cancer
patient management, there are limitations to this study.
First, the sample size of the entire data set was sufficient
to build strong predictors when considering all patients
and for ER-positive patients. However, when conducting
stratified analyses, sample size significantly decreased in
some cases (i.e. only 106 Basal-like patients), thus limit-
ing power for those subsets. This represents an alterna-
tive explanation for the failure to identify prognostic
signatures within those groups, although it is quite pos-
sible that almost all Basal-like patients do have an inher-
ently poor prognosis in the untreated setting and that
no identifiable “good prognosis signature” exists for
Basal-like tumors. Second, a challenge of this study was
the implementation of many published predictors onto a
common dataset, many of which used unique statistical
methods; we strove to implement each predictor as pub-
lished, however, almost all predictors “lost” genes due to
combining data across microarray platforms, and thus,
almost all predictors differed somewhat from their origi-
nal specification. Lastly, this dataset is comprised pri-
marily of tissue bank samples and therefore factors such
as patient selection may differ from what is observed in
a true population-based sampling of incident cases.
Despite these caveats, our analyses did identify robust
predictors for all patients and for ER-positive patients,
and confirmed the prognostic abilities of many pre-
viously published signatures. In addition, we demon-
s t r a t e dt h a tm o d e l sb u i l tu s ing clinical variables can be
improved with genomic information, and showed that
the best models are a combination of genomic and clini-
cal variables. Another implication of these data is that
prognostication for breast cancer patients is possibly
only relevant for ER-positive/Luminal patients; it does
not adequately prognosticate in ER-negative or HER2-
positive breast cancers. Similarly, a recent study suggests
a markedly poorer prognosis in even the smallest node-
negative HER2-positive tumors [75]. Additional data, or
methods, are still needed for prognostication in these
patients.
Clearly models focused on predicting chemotherapy
responsiveness would be highly relevant to ER-negative
tumors and breast cancer patients in general. To address
this predictive need, we successfully applied our model
building approach on a set of 225 T/FAC treated
patients and achieved AUC values of ~0.8. However, we
were unable to test if pCR predictors are of great value
for HER2-positive and Basal-like patients survival out-
comes due to the lack of a dataset that included out-
comes, neoadjuvant response and microarray data.
Lastly, some individual models, like the NKI 70-gene
signature [3,4], the OncotypeDX RS [5], the 76-gene
Rotterdam index [47] and the ROR-C model [46],
achieved comparable predictive abilities when compared
to the full new model containing ~20 modules com-
posed of thousands of genes and multiple clinical vari-
ables; we acknowledge that for the majority of these
predictors (excluding the OncotypeDX RS), the dataset
used here could be considered to be a training data set,
which likely over estimates their true prognostic powers.
However, the newly developed combined models did
use training and testing sets and barely outperformed
the aforementioned predictors, which suggests that not
much more prognostic powers are to be had by includ-
ing hundreds of signatures beyond the powers contained
within a well developed individual signature when com-
bined with the clinical variables. Ultimately, we envision
that additional data types like germline genotypes, spli-
cing information, microRNA profiles, DNA Copy num-
ber changes, phospho-proteomic patterns and gene
mutation information will lead to significant improve-
ments to the existing models, and in theory our model
building approach can incorporate these disparate data
types.
Conclusions
In this study, we have identified significant prognostic
models using clinical-pathological variables and 323
gene expression “modules” in patients with lymph node-
negative ER-positive breast cancer. Specifically, we show
that 1) the clinical variables alone build the least accu-
rate models, 2) genomic models alone are better than
clinical variables alone, and 3) a combined genomic and
clinical model is best, and thus, would be the most
helpful in the process of adjuvant decision-making for
node-negative ER-positive breast cancers. These findings
reinforce that clinical information still plays a key role
for prognostication in node-negative breast cancer
(especially in ER-positive disease), but also that genomic
variables provide important information not provided by
the classical clinical variables. Interestingly, we also
found that single module/signatures built for prognosis
( i . e .R O R - S ,N K I7 0 - g e n e ,O n c o t y p e D XR S ,R o t t e r d a m
76-gene index) can perform nearly as well as a combina-
tion of hundreds of signatures. Finally, although huge
advancements in prognostic models for breast cancer
are unlikely given the amount of work that has already
gone into biomarkers for breast cancer, we feel that our
advances are significant, even if the magnitude of the
effect is not large.
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Additional file 1: Supplemental materials and methods. This file
contains all the gene lists and methods used for the 323 modules
evaluated in this article.
Additional file 2: Supplemental data. This file contains additional
analyses and results.
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